One non-randomized open-label study, published over 2 separate articles, showed that 4-week liraglutide led to an improvement in a test of executive functioning (and possibly other cognitive measures) 178 and related increase in fronto-striatal volumes 179 , partly moderated by BMI and insulin resistance changes, in 19 people diagnosed with bipolar disorder or major depression
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
Includes pharmaceutical-grade GLP-1 medication (semaglutide), comprehensive medical consultation, injection training and all supplies, basic nutritional guidance, and follow-up scheduling
However, changing behaviors is notoriously challenging, requiring ongoing support, motivation, and personalized guidance
This has led to research into GLP-1 receptor agonists for neurodegenerative diseases
As a result, many are choosing to: Limit access Prefer one drug over another Or remove coverage entirely for weight-loss use Medicare Changes Are Coming but Not in April There is a notable update for Medicare beneficiaries, but it doesnt begin until July 1, 2026